Your browser doesn't support javascript.
loading
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel-Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro, Pilar; Garrido-Aranda, Alicia; Gallego, Elena; Sojo, Belén; Gálvez, Laura; Chica-Parrado, Rosario; Prieto, Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez, Martina; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo, Manuel; Alba, Emilio; Barragán, Isabel.
Affiliation
  • Onieva JL; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Xiao Q; Cancer Molecular Biology Laboratory (LBMC), Translational Research in Cancer Immunotherapy Group, Health and Medical Research Centre (CIMES), University of Malaga (UMA), Marques de Beccaria 3, 29010 Malaga, Spain.
  • Berciano-Guerrero MÁ; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
  • Laborda-Illanes A; Facultad de Medicina, Campus de Teatinos s/n, Universidad de Málaga, 29071 Malaga, Spain.
  • de Andrea C; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Chaves P; Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Piñeiro P; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Garrido-Aranda A; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
  • Gallego E; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Sojo B; Cancer Molecular Biology Laboratory (LBMC), Translational Research in Cancer Immunotherapy Group, Health and Medical Research Centre (CIMES), University of Malaga (UMA), Marques de Beccaria 3, 29010 Malaga, Spain.
  • Gálvez L; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
  • Chica-Parrado R; Facultad de Medicina, Campus de Teatinos s/n, Universidad de Málaga, 29071 Malaga, Spain.
  • Prieto D; Department of Anatomy, Physiology and Pathology, University of Navarra, 31008 Pamplona, Spain.
  • Pérez-Ruiz E; Department of Anatomy and Pathology, University of Navarra, 31008 Pamplona, Spain.
  • Farngren A; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Lozano MJ; Cancer Molecular Biology Laboratory (LBMC), Translational Research in Cancer Immunotherapy Group, Health and Medical Research Centre (CIMES), University of Malaga (UMA), Marques de Beccaria 3, 29010 Malaga, Spain.
  • Álvarez M; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
  • Jiménez P; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Sánchez-Muñoz A; Cancer Molecular Biology Laboratory (LBMC), Translational Research in Cancer Immunotherapy Group, Health and Medical Research Centre (CIMES), University of Malaga (UMA), Marques de Beccaria 3, 29010 Malaga, Spain.
  • Oliver J; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
  • Cobo M; Medical Oncology Intercenter Unit, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Regional and Virgen de la Victoria University Hospitals, 29010 Malaga, Spain.
  • Alba E; Cancer Molecular Biology Laboratory (LBMC), Translational Research in Cancer Immunotherapy Group, Health and Medical Research Centre (CIMES), University of Malaga (UMA), Marques de Beccaria 3, 29010 Malaga, Spain.
  • Barragán I; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, 29010 Malaga, Spain.
Int J Mol Sci ; 23(16)2022 Aug 15.
Article de En | MEDLINE | ID: mdl-36012390
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Inhibiteurs de points de contrôle immunitaires / Mélanome Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Int J Mol Sci Année: 2022 Type de document: Article Pays d'affiliation: Espagne Pays de publication: Suisse
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Inhibiteurs de points de contrôle immunitaires / Mélanome Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Int J Mol Sci Année: 2022 Type de document: Article Pays d'affiliation: Espagne Pays de publication: Suisse